Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meetin
Go back to Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meetin| (NASDAQ: CNTB) | Delayed: 2.22 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.22 | 52 Week High | $ | |||
| Open | $2.22 | 52 Week Low | $ | |||
| Day High | $2.22 | P/E | N/A | |||
| Day Low | $2.22 | EPS | $ | |||
| Volume | 457 | |||||
